Relmada Therapeutics, Inc.
DE ˙ DB ˙ US75955J4022
5,30 € ↓ -0,05 (-0,93%)
2026-06-04
AKTIENPREIS
SecurityDE:4E2 / Relmada Therapeutics, Inc.
InstitutionGeode Capital Management, Llc
Latest Disclosed Ownership848,683 shares
Latest Disclosed Value $ 5,909,987
Geode Capital Management, Llc reports 0.73% decrease in ownership of 4E2 / Relmada Therapeutics, Inc.

On May 15, 2026 - Geode Capital Management, Llc filed a 13F-HR form disclosing ownership of 848,683 shares of Relmada Therapeutics, Inc. (DE:4E2) valued at $4,667,756 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 854,932 shares of Relmada Therapeutics, Inc.. This represents a change in shares of -0.73% during the quarter. The current value of the position is $4,498,020 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F RELMADA THERAPEUTICS COM 75955J402 848,683 -6,249 -0.73 5,910 43.04 0.0002
2026-02-09 2025-12-31 13F RELMADA THERAPEUTICS COM 75955J402 854,932 558,717 188.62 4,131 594.29 0.0003
2025-11-12 2025-09-30 13F RELMADA THERAPEUTICS COM 75955J402 296,215 -6,139 -2.03 596 228.73 0.0000
2025-08-08 2025-06-30 13F RELMADA THERAPEUTICS COM 75955J402 302,354 471 0.16 182 123.46 0.0000
2025-05-13 2025-03-31 13F RELMADA THERAPEUTICS COM 75955J402 301,883 -955 -0.32 82 -48.41 0.0000
2025-02-12 2024-12-31 13F RELMADA THERAPEUTICS COM 75955J402 302,838 -1,664 -0.55 158 -84.08 0.0000
2024-11-12 2024-09-30 13F RELMADA THERAPEUTICS COM 75955J402 304,502 44,004 16.89 987 26.25 0.0001
2024-08-09 2024-06-30 13F RELMADA THERAPEUTICS COM 75955J402 260,498 4,411 1.72 782 -34.42 0.0001
2024-05-13 2024-03-31 13F RELMADA THERAPEUTICS COM 75955J402 256,087 12,674 5.21 1,191 18.27 0.0001
2024-02-13 2023-12-31 13F RELMADA THERAPEUTICS COM 75955J402 243,413 3,509 1.46 1,008 40.06 0.0001
2023-11-13 2023-09-30 13F RELMADA THERAPEUTICS COM 75955J402 239,904 5,542 2.36 720 24.83 0.0001
2023-08-11 2023-06-30 13F RELMADA THERAPEUTICS COM 75955J402 234,362 -267,981 -53.35 577 -49.25 0.0001
2023-05-15 2023-03-31 13F RELMADA THERAPEUTICS COM 75955J402 502,343 16,092 3.31 1,135 113,400.00 0.0001
2023-02-13 2022-12-31 13F RELMADA THERAPEUTICS COM 75955J402 486,251 -4,561 -0.93 2 -99.99 0.0002
2022-11-14 2022-09-30 13F RELMADA THERAPEUTICS COM 75955J402 490,812 -6,515 -1.31 18,169 92.39 0.0028
2022-08-12 2022-06-30 13F RELMADA THERAPEUTICS COM 75955J402 497,327 42,423 9.33 9,444 -23.08 0.0014
2022-05-13 2022-03-31 13F RELMADA THERAPEUTICS COM 75955J402 454,904 110,947 32.26 12,277 58.43 0.0015
2022-02-11 2021-12-31 13F RELMADA THERAPEUTICS COM 75955J402 343,957 90,254 35.57 7,749 16.54 0.0009
2021-11-12 2021-09-30 13F RELMADA THERAPEUTICS COM 75955J402 253,703 9,371 3.84 6,649 -14.99 0.0009
2021-08-13 2021-06-30 13F RELMADA THERAPEUTICS COM 75955J402 244,332 5,060 2.11 7,821 -7.16 0.0011
2021-05-12 2021-03-31 13F RELMADA THERAPEUTICS COM 75955J402 239,272 33,585 16.33 8,424 27.71 0.0013
2021-02-12 2020-12-31 13F RELMADA THERAPEUTICS COM 75955J402 205,687 5,437 2.72 6,596 -12.44 0.0011
2020-11-13 2020-09-30 13F RELMADA THERAPEUTICS COM 75955J402 200,250 2,007 1.01 7,533 -15.08 0.0015
2020-08-13 2020-06-30 13F RELMADA THERAPEUTICS COM 75955J402 198,243 90,554 84.09 8,871 141.52 0.0019
2020-05-14 2020-03-31 13F RELMADA THERAPEUTICS COM 75955J402 107,689 10,581 10.90 3,673 -3.01 0.0010
2020-02-20 2019-12-31 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 97,108 97,108 3,787 0.0008
2020-02-13 2019-12-31 13F RELMADA THERAPEUTICS COM 75955J402 97,108 3,787 0.0008
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.